OBJECTIVES:
According to World Federation of Hemophilia, more than 90% of cost of hemophilia treatment is the cost of factor replacement. Currently, 13 different Factor VIII products are available in Turkish market. These are classified as Љbio-equivalentЉ and these products are neither included in a willingness to pay threshold nor in a pharmacoeconomic analysis before the reimbursement decision. The aim of this study is determining the budget impact of possible cost minimization strategies in reimbursement of Factor VIII products via investigating current reimbursement conditions and evaluation of possible ways for inserting cost minimization from the Payer's perspective. METHODS: IMS data (September 2009 (September -2010 ) is evaluated for Factor VIII products in Turkish market. Current reimbursed prices are evaluated for determination of particular patterns of reimbursement. Annual volume of Factor VIII consumption and annual cost of Factor VIII consumption are linked and re-defined for cost minimization estimates in Microsoft 2003 Excel. TreeAgePro2011 is used for calculations and decision tree structuring. RESULTS: Annual consumption of Factor VIII products constitutes 128,319,000 IU and an annual cost of 129,806,872.88 TL. The Payer can imply cost minimization strategies (change reimbursement strategies and/or eliminating waste) resulting in gradual reduction from total expenditure as 2.6% (3,390,029.43 TL/year), 2.8% (3,610,300.16 TL/year), 5.7% (7, 357, 325.35 TL/year), 18.9% (24, 595, 818.19 TL/year) and 20.8% (27, 059, 457.55 TL/year) . CONCLUSIONS: Payer may apply following steps for cost minimization, therefore obtaining a positive budget impact for Factor VIII spending in Turkey; Step1: Evaluation of all Factor VIII products according to the reimbursed prices; Step2: Classification of reimbursement pattern for each product; Step3: Standardization of reimbursement patterns for all products; Step4: Promotion of differentiation for availability of forms; Step5: Monitoring annual budget impact effect of all previous steps. 
PSY12 COMPARISON OF THE MOST COMMON REASONS FOR INPATIENT ADMISSIONS AMONG FIBROMYALGIA PATIENTS ON DULOXETINE VERSUS PREGABALIN

OBJECTIVES:
To examine the most common reasons for inpatient admissions among fibromyalgia patients who initiated duloxetine or pregabalin. METHODS: Using a large US national commercial healthcare claims database, fibromyalgia patients aged 18-64 who initiated duloxetine or pregabalin in 2006 were identified. All patients included had 12-month continuous enrollment before and after the initiation, and at least 31 total duloxetine or pregabalin supply days over the 12-month post-index period. Propensity scoring was applied to construct duloxetine and pregabalin cohorts with similar demographics, pre-index clinical and economic characteristics, and pre-index treatment patterns. Reasons for inpatient admissions between the cohorts were examined. Logistic regressions were used to assess the contribution of duloxetine versus pregabalin initiation to the top reasons for inpatient admissions controlling for cross-cohort differences. RESULTS: Per our study design, duloxetine (nϭ3,711) and pregabalin (nϭ4,111) patients had similar demographics with a mean age of 51 years and 83% females. Both cohorts had similar co-morbidities, with cardiovascular disease being the most common.
Duloxetine and pregabalin patients, by the study design, also had similar total health care costs over the 12-month pre-index period ($18,970 vs. $19,019, pϭ0.994) with 22% contributed by inpatient care. Eight of the top 10 reasons for inpatient admissions over the 12-months post-index period were the same for both groups with intervertebral disc disorder, osteoarthritis of lower leg, and chest pain being the top 3 leading reasons. Controlling for cross-cohort differences, duloxetine patients were at a significantly lower risk for hospitalizations due to intervertebral disc disorder or major depression disorder (MDD) (odds ratiosϭ0.44, 0.81, respectively; both pϽ0.0001). CONCLUSIONS: Among similar commercially-insured fibromyalgia patients who initiated duloxetine or pregabalin, the leading reasons for inpatient admissions were somewhat different between groups. Compared to pregabalin initiators, duloxetine initiators tended to be less likely to have inpatient admissions due to intervertebral disc disorder or MDD. 
PSY13 COMPARING TOP REASONS FOR PRIMARY CARE OR SPECIALTY CARE VISITS AMONG FIBROMYALGIA PATIENTS INITIATED DULOXETINE VERSUS PREGABALIN
OBJECTIVES:
To examine the most common reasons for primary or specialty care visits among fibromyalgia patients initiated duloxetine or pregabalin. METHODS: Using a large US commercially-insured administrative claims database, we examined fibromyalgia patients aged 18-64 who initiated duloxetine or pregabalin in 2006. All patients were required to have 12 months of continuous enrollment prior to and after the initiation. Applying propensity scoring, we constructed the duloxetine and pregabalin cohorts to have similar demographics, comorbid medical conditions, prior healthcare utilization and costs, and prior medication use. Using the first diagnosis recorded in all outpatient claims, we examined the reasons for primary vs. specialty care over the 12-month post-index period. Controlling for cross-cohort differences, we assess the impact of duloxetine vs. pregabalin initiation on the top reasons for primary care or specialty care visits via logistic regressions. RESULTS: The study sample included 3,711 duloxetine and 4,111 pregabalin patients with a mean age of 51 years and around $19,000 prior total healthcare costs. Duloxetine and pregabalin patients shared 8 (9) out of the 10 top reasons for primary (specialty) care visits, with most of the prevalence rates/10,000 being higher (lower) among the duxeteine patients. Controlling for cross-cohort differences, duloxetine patients were more likely to have a primary care visit due to disorder of soft tissue, essential hypertension, or other general symptoms (odds ratiosϭ1.12, 1.16, 1.14, respectively), but less likely to go to specialty care due to disorder of soft tissue, nonspecific backache/other back/neck pain, or intervertebral disc disorder (odds ratiosϭ0.83, 0.69, 0.63, respectively) (all pϽ0.05). CONCLUSIONS: Among commercially-insured fibromyalgia patients who initiated duloxetine or pregabalin, the most common reason for primary or specialty care was somewhat different. Duloxetine initiators tended to be less likely to use specialty care, and more likely to use primary care for disorder of soft tissue. 
PSY14 DIFFERENCES IN OUTPATIENT CARE AMONG FIBROMYALGIA PATIENTS ON DULOXETINE VERSUS PREGABALIN
OBJECTIVES:
To examine the most common reasons for physician office visits, outpatient hospital visits, and emergency room (ER) visits among fibromyalgia patients who initiated duloxetine or pregabalin. METHODS: Commercially-insured fibromyalgia patients aged 18-64 who initiated duloxetine or pregabalin in 2006 were examined. All patients selected had continuous enrollment during the 12 months before and after the initiation. Each patient was classified into the duloxtetine or pregabalin cohort based on the index medication, and both cohorts were constructed via propensity scoring to have similar demographics, comoribidities, prior healthcare costs, and prior pain-related medication use. Reasons for physician office, outpatient hospital, and ER visits over the 12 months post-index period were examined for both cohorts. The impact of duloxetine vs. pregabalin initiation on the top reasons leading to physician office, outpatient hospital, or ER visits was examined via logistic regressions controlling for the cross-cohort differences. RESULTS: A total of 3711 duloxetine and 4111 pregabalin patients were included with a mean age of 51 years and 83% being female. Duloxetine and pregabalin patients had similar total healthcare costs ($18,970 vs. $19,019, pϭ0 .994) over the 12 months pre-index period, with 52-53% contributed by the outpatient care. Both groups shared 9 out of the top 10 reasons for physician office visits, 7 of the 10 most common reasons for outpatient hospital visits, and 8 of the top 10 reasons for ER visits. Controlling for cross-cohort differences, duloxetine patients were less likely to have a physician office visit due to nonspecific backache/other back/neck pain but more likely to go to the ER due to other general symptoms (odds ratiosϭ0.91, 1.43, respectively, both pϽ0.001). CONCLUSIONS: Among commercially-insured fibromyalgia patients who had similar demographic and clinical characteristics and initiated duloxetine or pregabalin in 2006, the leading reasons were somewhat different for physician office visits, outpatient hospital or ER visits. Erythropoiesis' Stimulating Factors (ESAs) are among the top ten therapeutic groups with the highest pharmaceutical expenditure in Greece. OBJECTIVES: To explore the penetration of ESAs in the Greek pharmaceutical market and differences in pricing levels between originals and biosimilars. METHODS: Data derived from the IKA-ETAM Social Security Fund, covering almost 50% of insured population. Consumption of ESAs (epoetin alfa, darbepoetin alfa, epoetin beta, methoxy polyethylene glycol epoetin beta, epoetin zeta) was collected from the Central & Peripheral Pharmacy, dispensing high value medicines for serious diseases on outpatient basis covering almost 70% geographical area of Greece. Consumption of epoetins was recorded from 2008 to 2010, classified per strength (IU/mcg), separated in originals and biosimilars. The average price per 1000IU of each category was also estimated for the respective years based on NHS hospital prices. RESULTS: ESAs consumption in 2008 and 2009 was approximately the same (26 & 27% respectively) while decreasing by 4% reaching 23% in 2010. A 13,8% decrease was also observed in IKA-ETAM total pharmaceutical expenditure in 2010. ESAs expenditure in 2008, was €41,4 million corresponding to 99% market share (MSH) of originals epoetins, leaving only 1% MSH in biosimilar epoetin zeta launched in that year. In 2009 ESAs expenditure reached €43 million, with 94% and 6% MSH for original and biosimilar ESAs respectively. In 2010 ESAs expenditure was almost halved (€22mil-lion), due to price cuts and stricter control of prescriptions. Specifically, the MSH of originals reached 81% and biosimilars 19% respectively. In the reported years prices of biosimilars were slightly different from that of originals, however as of 2011 higher price differences are observed, favoring the use of biosimilars. CONCLUSIONS: Biosimilars penetration in Greece is similar with EU, 6% and 6,64% in 2009 respectively, presenting an increasing rate in 2010. Under the economic recession Greece is experiencing, biosimilars seem to be a cost saving option. 
PSY15 STRIVING FOR AFFORDABLE TREATMENTS WITHIN THE GREEK ENVIRONMENT: DO EPOETIN BIOSIMILARS HELP?
PSY16 COST AND QUALITY OF LIFE BENEFITS OF FASTER BLEED RESOLUTION WITH AN RFVIIA ANALOGUE: A MATHEMATICAL SIMULATION STUDY FOR THE GERMAN POPULATION
OBJECTIVES:
On-demand treatment for haemophilia patients with inhibitors is burdensome to patients and practitioners. Newer bypassing agents with shortened bleed resolution time resulting in fewer infusions, may impact costs and patient quality of life (QoL). The study objective was to model the lifetime costs and healthrelated QoL outcomes associated with bypassing agents, recombinant activated Factor VIIa and plasma-derived activated prothrombin complex concentrate (rFVIIa, pd-aPCC) in Germany, and investigate the impact of faster bleeding resolution of a new rFVIIa analogue. METHODS: Assuming a German payer perspective, this literature-based model tracks a hypothetical cohort of severe haemophilia patients with inhibitors over their lifetime. A semi-Markov model was used to simulate patient movement through health states at 3-month intervals. Modeled outcomes include lifetime direct treatment costs, cost per bleeding episode, life-years, and quality-adjusted life years (QALYs) across a continuum of home and inpatient care. One-way sensitivity analyses were performed on all model variables and two-way sensitivity analyses on key variables. RESULTS: Using base-case assumptions from the literature, rFVIIa was associated with measurable lifetime cost savings compared with pd-aPCC (€ 2,962,833 vs. € 4,664,971, respectively) and reduced total cost per bleed compared with pd-aPCC (€ 17,614 vs. € 19,435, respectively) . Reducing the number of rFVIIa infusions per bleed from 2.3 to 1.5 resulted in incremental cost savings of € 248,033, while 20% utility improvement in rFVIIa conferred a 3.14 additional QALY gain. Sensitivity analyses confirmed the robustness of base case findings. CONCLUSIONS: This exploratory model is a valuable tool for physicians to assess the impact of current treatment patterns over a patient's lifetime and to potentially identify optimal practice patterns. Availability of bypassing agents with improved efficacy profiles could result in significant improvement of patient care. OBJECTIVES: Evaluate rate of flares in adult SLE patients with active antinuclear autoantibody positive SLE disease and estimate the incremental direct costs of flare management. METHODS: A multi-centre retrospective chart review study extracting patient characteristics, disease activity and severity, and medical resource utilization in 5 European countries (France, Germany, UK, Italy and Spain). Patients were stratified by disease severity at inclusion visit (50% severe) and followed-up for 2 years. Severe disease defined as having at least one major domain actively involved (renal, neurological, cardiovascular or respiratory) and requiring Ͼ7.5 mg/day of corticosteroids and/or immunosuppressants. A modification of SELENA-SLEDAI Flare Index collected retrospectively was used for identifying mild/ moderate and severe flares. Unadjusted mean costs associated with management of flares were assessed. Health care perspective and country specific data was used for resources and costs analysis. RESULTS: The total sample included 427 SLE patients (212 severe, 215 non-severe), mean age: 43.4 years, female: 90.5%. Total mean number of flares over the study period was 2.29 compared to 1.83 (pϽ0.001) for severe and non-severe patients respectively. Mean number of mild/moderate flares was 0.87 compared to 1.32 (pϽ0.001), while mean number of severe flares was 1.42 compared to 0.52 (pϽ0.001) for severe and non-severe patients, respectively. The mean two year costs for patients experiencing at least one flare over study period was €9607 compared to €3910 (pϽ0.001) without flares. Exploratory flare analysis showed a mean 2 year increase in costs of €4525 (pϽ0.01) per severe flare (no statistical significance for mild/moderate flares). CONCLUSIONS: Severe patients experience both a higher number of flares and more severe flares compared to non-severe patients. Patients experiencing at least one flare over the study period are 2.5 times more costly than patients without flares; the presence of severe flares in SLE patients has a significant impact on the healthcare system.
PSY17 RETROSPECTIVE CHART REVIEW STUDY OF THE COST OF CARE OF SYSTEMTIC LUPUS ERYTHEMATOUSUS (SLE) IN FIVE EUROPEAN COUNTRIES
